An APP gene test checks for disease-causing changes in the APP gene, which carries instructions for making amyloid precursor protein. It measures one rare inherited cause of early-onset Alzheimer's disease and misses common late-onset risk factors and most other inherited causes when ordered alone. Pathogenic APP variants alter amyloid processing and raise plaque formation, causing autosomal-dominant disease that begins before age 65. Because this pattern is uncommon, testing is used mainly during a workup for suspected familial early-onset disease, not for typical memory loss later in life.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What an APP test measures
- Who usually needs this testing
- What APP testing misses
- What it does not say about APOE and later life risk
- How to approach testing safely
What an APP test measures
The APP gene provides instructions for amyloid precursor protein. Enzymes cut that protein into amyloid-beta fragments, which can build up as plaques in Alzheimer's disease, according to the MedlinePlus Genetics page on the APP gene.
A positive result means a laboratory found a variant that changes amyloid processing in a way linked to early-onset disease. In practice, clinical testing uses next-generation sequencing of APP together with PSEN1 and PSEN2 to confirm diagnosis in a symptomatic patient or assess an at-risk relative.
Who usually needs this testing
The relevant group is small. Early-onset disease accounts for less than 10% of all Alzheimer's cases, and only about 10%-15% of those early-onset cases are explained by APP, PSEN1, or PSEN2 mutations, according to the National Institute on Aging fact sheet on Alzheimer's genetics.
Doctors consider panel testing when symptoms start before 65, especially with a parent or sibling affected young or with two or more close relatives affected across generations. The goal is diagnosis, family risk assessment, and planning, not screening for general brain health.
- Symptoms before age 65 with suspected Alzheimer's
- A family pattern suggesting dominant inheritance
- An at-risk adult relative seeking clear risk information
What APP testing misses
APP testing alone misses most mutation-positive families. Among familial early-onset cases with a known mutation, ARUP reports PSEN1 in 20%-70%, APP in 10%-15%, and PSEN2 in about 5%, according to the ARUP Consult page on early-onset Alzheimer's panel sequencing.
A negative result also does not rule out heritable early-onset disease. Some families have no detectable APP, PSEN1, or PSEN2 mutation, while other genetic contributors remain under study. A three-gene panel is therefore more informative than APP alone, but it still has limits.
What it does not say about APOE and later life risk
An APP test does not measure late-onset Alzheimer's risk from APOE e4. That variant raises risk but is neither necessary nor sufficient to cause disease, and it is generally left out of early-onset diagnostic panels, according to the 2023 PMC review of genetic testing for early-onset Alzheimer disease.
This distinction matters for families. A person can develop late-onset Alzheimer's without APOE e4, and many APOE e4 carriers never develop dementia. Families worried about risk after age 65 need a different discussion than families facing symptoms at 50.
How to approach testing safely
Joint guidelines from the American College of Medical Genetics and the National Society of Genetic Counselors recommend pre- and post-test counseling for APP and related testing. Counseling covers consent, possible results, family effects, work and insurance concerns, and plans for disclosure.
Those guidelines also advise against testing children and support a careful, Huntington-style disclosure process for adults without symptoms, with support available. An at-risk adult should meet with a genetic counselor before blood is drawn, bring a support person to result disclosure, and decide in advance who will receive the result.
